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Introduction
Overactive bladder (OAB) is a clinical symptom complex defined as urinary urgency, with or without urgency urinary incontinence (UUI), usually with daytime frequency and nocturia, in the absence of urinary tract infection or other obvious pathology [1] OAB is a common condition with population-based estimates of 13-36% in women and 11-22% in men [2] . The prevalence of OAB and associated UUI increases with advancing age [3] . OAB severity can progress over time; individuals who initially present with OAB without UUI may subsequently develop UUI [4] . Both urinary urgency and UUI are associated with considerable comorbidities in elderly persons, including falls and fractures, skin infections, functional impairment and depression [5, 6] . Recommended initial therapy for OAB includes behavioural and conservative interventions, such as lifestyle modification, bladder training, and pelvic floor muscle exercises for urgency suppression [7] . Should this fail to achieve the required effect, then pharmacological therapy is recommended. The current first line therapy for OAB is antimuscarinic agents [8] , which are both effective and well tolerated in clinical trials [9] .
Until relatively recently, there has been a dearth of data which specifically dealt with the pharmacological treatment of OAB in older patients. Because of generalised concerns about the use of anticholinergics, clinicians have been reluctant to prescribe these drugs [10] . This has led to considerable under treatment of the condition despite little evidence, regarding the use of bladder antimuscarinics, which support these concerns [11] [12] [13] [14] [15] . Older patients commonly have both co-morbidity and take multiple coexisting medications; the existence of which may either limit the efficacy of OAB treatments or lead to an increase in associated adverse events, adding to this reluctance to treat.
The bladder antimuscarinic agent fesoterodine has been extensively investigated in the treatment of OAB in patients aged 65 years or older. Following oral administration, fesoterodine is absorbed almost completely from the gut. Intake of fesoterodine with or without food does not alter the bioavailability which is approximately 52%. Fesoterodine is rapidly and extensively converted to its primary metabolite, 5-hydroxymethyltolterodine (5-HMT), by ubiquitous esterases [16, 17] . Despite potent antimuscarinic activity, 5-HMT has a low propensity for central nervous system (CNS) penetration and is transported from the CNS by the active efflux transporter P-glycoprotein [17, 18] . The drug and its metabolites are predominantly eliminated by renal excretion and, to a minor amount, in the faeces; patients with different stages of renal function impairment and those with mild to moderate liver insufficiency have a similar elimination half-life of 7-9 h. The pharmacokinetic profile is largely unaltered regardless of differences in age, sex or ethnicity of patients [19] .
Data have been reported from prospective studies and pooled analyses for both community-dwelling elderly patients and those with medical complexity [20] [21] [22] . A previous narrative review of the effect of fesoterodine in older people showed, trial by trial, the efficacy of the compound in treating OAB in older adults [23] . The aim of this study, which pooled all available data from fesoterodine trials in which a patient over 65 years of age was enroled, was to examine all available efficacy and safety information to reaffirm the efficacy of the drug and additionally to use these data explore the relationships between treatment emergent adverse events (TEAEs), central nervous system TEAEs and coexisting polypharmacy and co-morbidity.
Methods
Ten phase III-IV, double-blind, placebo-controlled fesoterodine studies, the details and design of which are shown in Table 1S (Supplementary data are available in Age and Ageing online), provided data for this analysis. Efficacy analyses were based on the Full Analysis Set, defined as all randomised patients who took at least one dose of the study drug, had a baseline UUI > 0 and baseline efficacy assessment. The safety analysis set included all subjects who were randomised and received at least one dose of double-blind study medication. Missing data were imputed using the last observation carried forward method. For the majority of analyses, data were grouped into four age subgroups: 65-74, 75-84, ≥75 and ≥85 years old; data for males and females were combined. For the descriptive adverse events analyses, data were grouped into 65-74 and ≥75 years old. In addition, a logistic regression analysis, where TEAE incidence was predicted by treatment (placebo, fesoterodine 4 mg, fesoterodine 8 mg), study, prior antimuscarinic treatment (yes, no), number of coexisting medications, number of concomitant diseases and all possible combinations of two-way interaction terms with treatment was conducted. The probabilities of having TEAE were calculated for each patient group.
Efficacy endpoints
The change from baseline to Week 12 in the following efficacy endpoints were examined: UUI episodes/24 h, 24 h micturition frequency and nighttime micturition frequency, number of urinary urgency episodes/24 h, number of nighttime urgency episodes, Patient Perception of Bladder Condition [24] Scores (not collected as part of study A0221048), and OAB questionnaire (OAB-q) [25] total and subdomain scores (symptom bother score, coping, concern, sleep and social interaction, total HRQL; not collected as part of studies SP583 and SP584). Bladder diary dry rate, defined as an absence of UUI, normalised urinary frequency rate (no of micturitions <8) and the absence of urgency as measured by the Urinary Sensation Scale [26] (USS, <2) were reported at 12 weeks. Numbers and frequencies of TEAEs and treatment emergent events (treatment-related) were calculated and the association between these, numbers of coexisting comorbidities, coexisting medications and previous antimuscarinic use reported at baseline were examined. Central nervous system TEAEs were examined separately.
Analysis
Summary descriptive statistics for the continuous efficacy endpoints, including cell counts and percentages, were calculated. Change from baseline to Week 12 in continuous efficacy endpoints was analysed with an ANCOVA model. The model included baseline values as a covariate with treatment and study as cofactors. The ANCOVA model was applied to each age category separately. Results were reported as the P-value from the treatment comparison, fesoterodine (8 and 4 mg combined) versus placebo, the least squares (LS) mean and standard error (SE) for change from baseline for each treatment, the LS mean difference and SE between treatments, and the 95% confidence interval of the LS mean difference. For PPBC, the CochranMantel-Haenszel (CMH) test row mean scores test with modified ridit scoring to compare sets of ordered qualitative data, stratified by study were used and summary statistics calculated. Differences in proportions were compared with the Chi-square test. Statistical significance was conventionally set at the 5% level.
Results Population
Overall, 4,040 patients participated in the included trials, this comprised 1,311 assigned to placebo, 999 to fesoterodine 4 mg, and 1,730 to fesoterodine 8 mg. Disease variables, health related quality of life scores and distributions of coexisting medications and concomitant conditions by age group for all patients with urgency incontinence at baseline are shown in Table 2S (Supplementary data are available in Age and Ageing online). At baseline, 1,546 (55%) of patients aged 65-74 years were taking more than 5 medications versus 696 (45%) of patients aged ≥75 years (P = 0.0001). However, 944 (61%) of those in the group ≥75 years of age had more than 5 concomitant conditions at baseline versus 1,469 (52%) of those in the younger age group (P < 0.0001). The ranges for coexistent medications and concomitant conditions at baseline for each age group were wide Figure 1S (Supplementary data are available in Age and Ageing online).
Efficacy
Fesoterodine treatment, expressed as change over 12 weeks, was associated with statistically significant reductions in all disease-related variables when compared to placebo (Table 1) . These findings held for both the 65-74-year age group and for those patients aged ≥75 years. Comparison of patient reported outcomes revealed similar statistically significant changes associated with fesoterodine treatment compared to placebo. Of the 65-74-year age group, 40.1% (versus 25.1% placebo treated) of fesoterodine treated patients experienced a major improvement in the PPBC score as did 34.4% (versus 21.2% placebo treated) of the ≥75-year age group.
Safety
The numbers of patients reporting adverse events by severity, including withdrawals, both permanent and temporary dose reductions, are shown in Table 3S dose or withdrew from therapy with placebo, fesoterodine 4 mg or fesoterodine 8 mg, respectively. Patients treated with fesoterodine were significantly more likely to report a TEAE compared to placebo treated patients; the odds ratio (OR) for fesoterodine 4 mg was 2.32 (95% CI: 2.056-2.627, P < 0.0001) and the OR of fesoterodine 8 mg was 3.087 (95% CI: 2.792-3.413, P < 0.0001).
TEAE, coexisting medications and concomitant conditions
Significant effects of coexisting medications and concomitant diseases were observed. There was a significant increase in the likelihood of reporting a TEAE in association with an increase in the number of coexistent medications; the OR increased by a factor 1.028 per medication increase (95% CI: 1.0143-1.044, P < 0.0003). For the number of concomitant diseases, the OR of having a TEAE level increase in the number of concomitant diseases was 1.058 (95% CI: 1.044-1.072, P < 0.0001). The cumulative probability of reporting a TEAE associated with number of concomitant conditions and coexisting medications at baseline by age group is shown in Figure 1 . The distribution of TEAE associated with each category of concomitant medication or coexisting condition at baseline by age group is shown in Table 2 . TEAEs of the CNS were few across the entire population, and there was no clear cumulative effect associated with increasing numbers of coexisting medications at baseline. Only insignificant effects were identified depending upon prior antimuscarinic exposure OR 1.004 (95% CI: 0.913-1.103, P = 0.9416).
Discussion
This pooled analysis explored the efficacy and safety of fesoterodine in patients aged 65-74 or > 75 years who were included in all phase III and IV studies to date. Fesoterodine exposure was associated with statistically and clinically significant improvements in the great majority of disease and patient reported variables after 12 weeks in both groups of older patients. Fesoterodine effects on nocturia reached statistical significance but, the effect is small and of questionable clinical utility [27] . Fesoterodine exposure led to highly statistically and clinically meaningful improvements across all included patient reported outcomes regardless of the age group, reaffirming the findings of individual studies including older patients. OAB has its greatest prevalence in the elderly and, thus, data such as those presented here are of great relevance to clinical practice. This study noted a wide distribution of concomitant conditions and coexisting medication use in older patients recruited into the included fesoterodine studies. A lower proportion of patients aged ≥75 years took more than 5 coexisting medications than those aged between 65 and 74 years at trial entry, perhaps suggesting that this group of patients was 'fitter' than those in the general population. However, the older age group did report more concomitant conditions at baseline. This may suggest that these conditions were less 'serious' as they did not prevent trial entry or may not have interfered with daily living. Adverse events were more common in those exposed to fesoterodine compared to placebo, as might be expected. These findings are consistent with the previous pooled analysis and pre-planned 12-week studies of fesoterodine in older people [20] [21] [22] .
This study examined the association of coexisting medications and concomitant conditions at baseline with TEAEs. For each increase in the number of coexisting medications reported at baseline, the OR of reporting a treatment emergent adverse event increased by a factor 1.028. For each increase in the number of concomitant conditions this was 1.058. This suggests that, in general, concomitant conditions have a greater influence on the likelihood of an adverse event being reported than the number of medications. Reassuringly, the number of CNS adverse events was low across all categories of concomitant disease and coexisting medications. The number of observed CNS-related adverse Table 2 . All cause-treatment emergent adverse events (TEAEs) and central nervous system (CNS) events by number of concomitant medications and concomitant conditions at baseline events was not associated with fesoterodine dose. There was also no consistent effect of age on the likelihood of a CNS-related adverse event being reported. These data add to that available for antimuscarinic treatment of older patients and should add confidence to the findings of a recent systematic review and Delphi process examining the available evidence for medications for lower urinary tract symptoms in older persons [28] . Like all studies of this nature, these analyses have limitations. Data can only be reported on older persons included in clinical trials and, except for those specifically performed in community dwelling [21] and vulnerable elderly [22] , enroled patients may not be representative of the general older population. Additionally, specific categories of medication were not separately analysed. Reports, for example, of cognitive adverse events and even dementia [29] occurring in association with a high anticholinergic load may have made a sub-analysis attractive but, given the low number of index events, the likelihood of useful information resulting from this would be minimal. In addition, the exposure time in the studies included here would in all probability have been too short. Data do suggest that, in the short term, in the cognitively intact older person, fesoterodine is not associated with cognitive impairment [30] .
In a similar fashion, despite the wide range of concomitant diseases, this study did not perform any sub-analyses of those which might be considered 'more serious'. The small numbers of patients with specific categories of coexistent condition in combination with study exclusion criteria would in all probability render such analyses of little value. The safety of fesoterodine in older persons is well established in both randomised, placebo-controlled and longer term open label studies of older patients [31] . This study allows us to counsel caution in the treatment of highly multimorbid patients and suggest that they have regular clinical review given their increased propensity to adverse events.
In conclusion, the findings from this pooled analysis have confirmed the clinical efficacy and safety of fesoterodine for the treatment of OAB in patients aged 65 years or older. This study has also demonstrated the additional impact of polypharmacy and multimorbidity on the likelihood of experiencing a treatment-related adverse event.
Key points
• Fesoterodine is efficacious in OAB treatment in older patients.
• The number of concomitant conditions at baseline has a greater influence on the likelihood of reporting an adverse event.
• The number of CNS TEAE associated with fesoterodine treatment in older patients is low.
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